CHMP Negative on Vivus' Qsiva - Analyst Blog


Shutterstock photo

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend the approval of Vivus Inc. 's ( VVUS ) weight-loss drug, Qsiva. The CHMP arrived at the decision at its October 15-18 meeting.

The CHMP rendered a negative opinion due to concerns over the potential cardiovascular and central nervous system effects associated with the long-term use, teratogenic potential and use by patients for whom Qsiva is not meant. Vivus intends to appeal against the negative opinion. The company also intends to request the CHMP to re-examine its negative opinion.

The negative opinion issued by the CHMP did not come as a surprise. Last month, Vivus had announced that it expected the CHMP to recommend against the approval of Qsiva in Europe. The company's expectation was based on a preliminary feedback provided by the CHMP.

We note the drug is already available in the US under the trade name Qsymia. Qsymia was approved by the US Food and Drug Administration (FDA) in July 2012. The FDA cleared Qsymia as an adjunct to a healthy diet (low on calories) and increased physical activity for chronic weight management in obese (Body Mass Index, or BMI - 30 or more) or overweight (BMI - 27 or more) adults suffering from at least one weight-related co-morbid condition.

Neutral on Vivus

We currently have a Neutral recommendation on Vivus. The stock carries a Zacks #3 Rank (Hold rating) in the short run. We note that rival company Arena Pharmaceuticals Inc. ( ARNA ) is preparing for the launch of its obesity drug Belviq along with its partner Eisai and Co Ltd. ( ESALY ), which got FDA approval in June 2012. Orexigen Therapeutics, Inc. ( OREX ) is also developing a candidate, Contrave, targeting the lucrative obesity market.

ARENA PHARMA (ARNA): Free Stock Analysis Report

(ESALY): ETF Research Reports

OREXIGEN THERAP (OREX): Free Stock Analysis Report

VIVUS INC (VVUS): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: ARNA , CHMP , ESALY , OREX , VVUS

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by